Sort   by:  
 Page size 
UnknownCase report: North Carolina macular dystrophy misdiagnosed as congenital ocular toxoplasmosis.
Not available
S-EPMC6857771 | biostudies-literature
UnknownGeneration and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.
Not available
S-EPMC4956256 | biostudies-literature
UnknownDiscussing Out-of-Pocket Expenses During Clinical Appointments: An Observational Study of Patient-Psychiatrist Interactions.
Not available
S-EPMC5565142 | biostudies-literature
UnknownSubtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
Not available
S-EPMC4895009 | biostudies-literature
UnknownPhase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Not available
S-EPMC7823071 | biostudies-literature
UnknownPlasma extracellular vesicles released after severe burn injury modulate macrophage phenotype and function.
Not available
S-EPMC8716518 | biostudies-literature
UnknownALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.
Not available
S-EPMC6890176 | biostudies-literature
UnknownIntervening on exercise and daylong movement for weight loss maintenance in older adults: A randomized, clinical trial.
Not available
S-EPMC8711609 | biostudies-literature
UnknownChanges in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.
Not available
S-EPMC3689341 | biostudies-literature
UnknownSafety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Not available
S-EPMC10986991 | biostudies-literature
Sort   by:  
 Page size